Pre-Market Boom! Hot Stocks Revealed

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


9X better than the S&P 500

Multimillionaire Trader Nate Bear just keeps winning: thanks to his One Ticker Payouts strategy that he revealed back in August, he's put up a 52% total return...Which has beat the market's performance by nearly 9x! You can get access to this week's trade...

Click here to see the details >>>

Happening Today

✓ 09:45 AM ET – S&P Global US Manufacturing PMI (Mar)

✓ 10:00 AM ET – ISM Manufacturing PMI (Mar)

✓ 10:00 AM ET – ISM Manufacturing Prices (Mar)


Stock futures show mixed signals: Dow Jones and S&P 500 inch up slightly, while NASDAQ 100 dips 0.12%.



⬆️ 0.11% 



⬆️ 0.12%



⬇️ -0.12%


All eyes on Energy as it jumps 1.10% today, Information Technology on the other hand dips 0.11%.




Consumer Discretionary


-0.14% 🔴

Consumer Staples


+0.17% 🟢



+1.10% 🟢



+0.57% 🟢

Health Care


+0.11% 🟢



+0.07% 🟢



+0.26% 🟢

Real Estate


+0.69% 🟢

Information Technology


-0.11% 🔴

Communication Services


-0.30% 🔴



+0.76% 🟢


Election Shock on August 19th?

In less than 258 days, I expect the biggest presidential election shock since 1968. 

Forget about Donald Trump... And forget about Joe Biden... Instead, I believe the unexpected is barreling toward America. And I believe the aftermath will transform this country forever. 

Click here now to see the evidence I've gathered. 

Unusual Volume

📈 Gamida Cell Ltd (GMDA) declined -39.02% to $0.04 on a whopping 89.18 million shares traded.

📈 Investors went wild, sending Biodexa Pharmaceuticals Plc ADR (BDRX) stock soaring 88.59% to $1.62 on a massive volume of 88.37 million shares after the company released that it is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults; two aggressive brain cancers with universally poor prognoses.

📈 Abnormal activity shook Akanda Corp (AKAN), pushing it down -29.29% to $0.12 on a whopping 80.34 million shares traded. The company announced Canmart's plans for Facebook and Instagram Social Shopping Technology Integration.

📈 Roivant Sciences Ltd (ROIV) stock recently closed -2.77% lower at $10.54 on substantial volume of 65.65 million shares.

📈 Akebia Therapeutics Inc. (AKBA) decrease by -18.30% in a single trading session, with abnormally high trading volume of 61.07 million shares following the receipt of FDA approval of Vafseo® (vadadustat) tablets for the treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis.


Elon's Secret "A.I. 2.0" Project

Luke Lango, the man who picked Tesla before it sky-rocketed 1,000%+, has traveled all the way to the Tesla Gigafactory in Texas to reveal Elon's hidden A.I. project.

It's known as "A.I. 2.0", and even though it's not yet known, or available to the general public, Luke Lango has found a "backdoor" method to claim a stake before it goes mainstream. 

Click here now to discover how to claim a stake in Elon's "A.I. 2.0" project  

Premarket Movers

Sunshine Biopharma, Inc. (SBFM) experiences a substantial 121.65% surge in pre-market trading after announcing operating results for the fiscal year ended December 31, 2023.

Galera Therapeutics, Inc. (GRTX) sees a significant 47.93% increase, reaching a pre-market price of $0.20 after releasing fourth quarter and full year 2023 financial results.

SPAR Group, Inc. (SGRP) demonstrates a noteworthy 40.26% surge, with a pre-market price of $1.36 after announcing sale of interest in South Africa and Brazil.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































DeFi Coin Triggers All "Buy" Signals And Could Break Out Soon

Some are calling this the most promising DeFi project since Ethereum itself.

Here's the #1 DeFi Coin Set to Soar. While Bitcoin grabs headlines, this lesser known DeFi coin is quietly gearing up for a monster rally. Experts say now is the time to buy before it reaches escape velocity.

Discover our top DeFi pick for potentially massive gains now (before it's too late).

Important FDA 

Recently Announced

Regeneron Pharmaceuticals (REGN) faced a setback with the FDA's issuance of Complete Response Letters (CRLs) for odronextamab on March 25, 2024. The drug, intended for relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma, awaits further evaluation to address regulatory concerns.

Esperion Therapeutics (ESPR) received positive news from the FDA on March 22, 2024. The agency granted broad new labels for NEXLETOL and NEXLIZET, marking a significant advancement in cardiovascular care. This expanded label allows for the prevention of heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.

Upcoming Announcements

VANDA PHARMACEUTICALS (VNDA) eagerly awaits the FDA's decision on April 2, 2024, regarding the expanded use of Fanapt for the treatment of bipolar I disorder in adults. This decision holds significant potential for patients and could represent a notable expansion in the treatment options available for this challenging condition.

Supernus Pharmaceuticals, Inc. (SUPN) awaits the FDA's decision on SPN-830 for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease on April 5, 2024. With the resubmission of the New Drug Application (NDA), the company aims to address previous regulatory concerns and bring a potentially valuable therapeutic option to patients managing Parkinson's disease.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.